Publications by authors named "Ermira Pazolli"

Claim this Profile
D
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce

Cancer Discov· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, Bryanna L Norden, Nicholas Chevalier, Ermira Pazolli

Cancer Discov· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators.
Daniel Aird, Teng Teng, Chia-Ling Huang, Ermira Pazolli, Deepti Banka

Nat Commun· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Michael Seiler, Akihide Yoshimi, Rachel Darman, Betty Chan, Gregg Keaney, Ermira Pazolli

Nat Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors.
Kevin C Flanagan, Elise Alspach, Ermira Pazolli, Shankar Parajuli, Qihao Ren

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Hazel M Weir, Robert H Bradbury, Mandy Lawson, Alfred A Rabow, David Buttar, Ermira Pazolli

Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p38MAPK plays a crucial role in stromal-mediated tumorigenesis.
Elise Alspach, Kevin C Flanagan, Xianmin Luo, Megan K Ruhland, Hui Huang, Ermira Pazolli

Cancer Discov· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression.
Ermira Pazolli, Elise Alspach, Agnieszka Milczarek, Julie Prior, David Piwnica-Worms

Cancer Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.
Xianmin Luo, Megan K Ruhland, Ermira Pazolli, Anne C Lind, Sheila A Stewart

Mol Cancer Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Senescent stromal-derived osteopontin promotes preneoplastic cell growth.
Ermira Pazolli, Xianmin Luo, Sarah Brehm, Kelly Carbery, Jun-Jae Chung

Cancer Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Senescence: the good the bad and the dysfunctional.
Ermira Pazolli, Sheila A Stewart

Curr Opin Genet Dev· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis